ReviewJournal of thoracic disease2018
Cell therapy in acute respiratory distress syndrome.
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II.Stem cell research & therapy · 2022Trial
- MFGE8 regulates the EndoMT of HLMECs through the BMP signaling pathway and fibrosis in acute lung injury.Respiratory research · 2025Article
- Hypercapnia outcome in COVID-19 acute respiratory distress syndrome patients on mechanical ventilator: A retrospective observational cohort.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2025Article
- Therapeutic characteristics of alveolar-like macrophages in mouse models of hyperoxia and LPS-induced lung inflammation.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Neutrophils and the Systemic Inflammatory Response Syndrome (SIRS).International journal of molecular sciences · 2023Review
- Cyclic Phytosphingosine-1-Phosphate Primed Mesenchymal Stem Cells Ameliorate LPS-Induced Acute Lung Injury in Mice.International journal of stem cells · 2023Article
- Nebulized mesenchymal stem cell derived conditioned medium amelioratesFrontiers in medicine · 2023Article
- Regenerative medicine in lung diseases: A systematic review.Frontiers in veterinary science · 2023Review
- Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.Frontiers in immunology · 2022Review
- Review
- Extracellular Vesicles: A New Paradigm for Cellular Communication in Perioperative Medicine, Critical Care, and Pain Management.Anesthesia and analgesia · 2021Review
- Multifunctional and Self-Healable Intelligent Hydrogels for Cancer Drug Delivery and Promoting Tissue Regeneration In Vivo.Polymers · 2021Review
- Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.Cytokine & growth factor reviews · 2021Review
- Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review.World journal of virology · 2021Review
- COVID-19 and graft-versus-host disease: a tale of two diseases (and why age matters).Laboratory investigation; a journal of technical methods and pathology · 2021Review
- Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.Stem cell reviews and reports · 2021Article
- Viability assessment of human peripheral blood-derived stem cells after three methods of nebulization.American journal of stem cells · 2021Article
- Studies on the effects of bone marrow stem cells on mitochondrial function and the alleviation of ARDS.Molecular and cellular biochemistry · 2021Article
- Persistency of Mesenchymal Stromal/Stem Cells in Lungs.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) is driven by a severe pro-inflammatory response resulting in lung damage, impaired gas exchange and severe respiratory failure. There is no specific treatment that effectively improves outcome in ARDS. However, in recent years, cell therapy has shown great promise in preclinical ARDS studies. A wide range of cells have been identified as potential candidates for use, among these are mesenchymal stromal cells (MSCs), which are adult multi-lineage cells that can modulate the immune response and enhance repair of damaged tissue. The therapeutic potential of MSC therapy for sepsis and ARDS has been demonstrated in multiple
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.